TOPLINE:
Sarcopenia, a hallmark of cancer cachexia, is associated with poor outcomes in chimeric antigen receptor (CAR) T-cell therapy, which can exacerbate muscle loss through inflammatory responses. The relationship between CAR T-cell therapy, sarcopenia, and metabolism requires further investigation to improve patient outcomes.
METHODOLOGY:
- Researchers measured skeletal muscle index from clinical images in 83 patients with large B-cell lymphoma at baseline and days 30 and 90 post-therapy.
- Serum metabolomics analysis was performed in 57 patients during the first 4 weeks.
- Patients received axicabtagene ciloleucel, tisagenlecleucel, or lisocabtagene maraleucel in a standard-of-care setting at Moffitt Cancer Center between December 2017 and March 2022.
- Analysis included measurement of tissue cross-sectional areas using…